HealthCare Global Enterprises Board Approves ₹425 Crore Rights Issue at ₹512 Per Share

HealthCare Global Enterprises is set to raise up to ₹425 crore through a rights issue at ₹512 per share, with a 1:17 ratio for eligible shareholders.

Reader Takeaway: Capital infusion to bolster finances; dilution to impact existing shareholders.

What just happened (today’s filing)

The Board of Directors of HealthCare Global Enterprises Limited (HCG) has approved a Rights Issue to raise up to ₹42,500 lakh (₹425 crore).

The issue price is fixed at ₹512 per share (face value ₹10, premium ₹502).

Eligible shareholders will receive 1 Rights Equity Share for every 17 held.

The Record Date for this issue is set as March 2, 2026, with the issue opening on March 11 and closing on March 25, 2026.

Why this matters

This capital raise is crucial for HCG, a leading oncology and fertility care provider, to strengthen its balance sheet and fund its growth ambitions.

A rights issue allows existing shareholders to increase their stake and participate in the company's future without the company incurring additional debt.

The infusion of capital is expected to provide financial flexibility, particularly after significant capital expenditure in recent years.

The backstory (grounded)

HCG has been on an expansion drive, undertaking substantial capital expenditure of around ₹800-900 crore over the last two years, which increased its total debt to ₹1,837.22 crore by FY25.

Recently, KKR acquired a majority stake in HCG from CVC, a move expected to bring strategic alignment and financial backing to the company's growth plans.

The company has also approved investments totaling ₹150 crore in its wholly-owned subsidiaries by March 31, 2026, for working capital and repayment of dues.

What changes now

Upon successful completion, the equity share capital of HCG will increase.

The total number of outstanding equity shares is projected to rise from approximately 141 million to about 149.3 million, assuming full subscription.

This capital infusion aims to support ongoing operational expansion and potentially reduce leverage.

Risks to watch

The Board or Rights Issue Committee can extend the issue period by up to 30 days, potentially delaying capital infusion.

Rights Entitlements not applied for by the closing date will lapse, meaning non-participating shareholders will forfeit their rights.

HCG's debt levels remain a key consideration, with its debt-to-equity ratio at 177.9% as of FY25.

Peer comparison

HCG operates in a competitive landscape alongside major players like Apollo Hospitals, Max Healthcare, and Fortis Healthcare. Apollo Hospitals is India's largest integrated provider with over 8,000 beds and FY25 revenue of ₹21,794 crore. Max Healthcare, known for tertiary care, has a market cap exceeding ₹93,200 crore and FY25 revenue of ₹7,028 crore. Fortis Healthcare, with approximately 5,554 beds, reported FY25 revenue of ₹7,783 crore and holds a market cap around ₹69,000 crore.

Context metrics (time-bound)

• Q3 FY26 Revenue stood at ₹6,331 million, with adjusted EBITDA at ₹1,108 million.
• As of FY25, the company reported total debt of ₹17,700 million and a debt-to-equity ratio of 177.9%.

What to track next

Submission of the Letter of Offer to SEBI, BSE, and NSE for their respective approvals.

Subscription levels during the Rights Issue period (March 11-25, 2026).

How the company utilizes the raised capital and its impact on future financial metrics.

Completion of KKR's integration and any strategic shifts it entails.